The agreement gives J&J access to bapineuzumab, a closely watched experimental Alzheimer's treatment that is in late-stage human studies but whose prospects remain uncertain.
Friday, July 03, 2009
Are J&J loosing their minds?
Johnson & Johnson on Thursday said it will buy an 18.4% stake in Irish biotech company Elan Corp., in a $1.5 billion bid to crack the elusive but potentially lucrative market for Alzheimer's disease treatments.
The agreement gives J&J access to bapineuzumab, a closely watched experimental Alzheimer's treatment that is in late-stage human studies but whose prospects remain uncertain.
The agreement gives J&J access to bapineuzumab, a closely watched experimental Alzheimer's treatment that is in late-stage human studies but whose prospects remain uncertain.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment